Ensayos clínicos

Inclusion Criteria:

- Have a histologically confirmed diagnosis of advanced (unresectable, recurrent, and/or
metastatic) endometrial carcinoma that is incurable and for which prior standard
first-line treatment has failed.

- Prior to Cycle 1 Day 1 (C1D1), documentation of tumor dMMR/MSI-H status must be
available based on local testing.

- Must have progressed on or after at least 1 (but no more than 2) prior line(s) of a
systemic chemotherapy regimen for unresectable and/or metastatic endometrial cancer of
which at least 1 regimen of platinum-based treatment unless participant is ineligible
for or intolerant to platinum.

- Cohort A only: Must be treatment naive for CPIs including PD-1 or PD-L1 inhibitors and
other immune CPIs (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT).

- Cohort B only: Must have received and progressed on or after prior treatment with a
PD-1/PD-L1 inhibitor alone or in combination. Moreover, the participant's duration of
CPI containing treatment and best overall response (BOR) is known, and participant has
received a minimum of 2 cycles of CPI.

Exclusion Criteria:

- Histological diagnosis of carcinosarcoma, malignant mixed M?llerian tumor, endometrial
leiomyosarcoma, or endometrial stromal sarcomas.

- Any prior treatment with any type of antitumor vaccine, or autologous cell
immunotherapy.

- Radiotherapy within 14 days before the planned first dose of trial treatment with
exception of palliative radiotherapy to bone lesions.

- Treatment with an anticancer agent, including investigational vaccines within 28 days
before or 5 times t1/2, whichever is shorter, prior to the planned first dose of trial
treatment or is currently enrolled in an interventional trial.

- Prior treatment with live, attenuated vaccines within 30 days prior to initiation of
trial treatment.

- Received granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage
colony-stimulating factor (GM-CSF) support within 4 weeks before the planned first
dose of trial treatment.

- Cohort A only: Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg,
anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell
receptors (eg, 4-1BB, OX40)

- Cohort B only:

- Known history of Grade 3 or higher immune-related adverse events (irAEs) that led
to treatment discontinuation of a prior immunotherapy treatment

- Exposure to any of the following prior therapies/treatments within the specified
timeframes:

- Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg, anti-CTLA-4,
anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg,
4-1BB, OX40)

- PD-1/PD-L1 antibody within 28 days before the planned first dose of trial
treatment.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/27/23. Questions regarding updates should be directed to the study team contact.